Loading stock data…
HALO
$66.35+0.48 (+0.73%)
Pre-Market$65.48-0.87 (-1.31%)· Last close May 6
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Halozyme Therapeutics, Inc. in the Healthcare sector is trading at $66.35. The stock is currently 19% below its 52-week high of $82.22, remaining 3.3% below its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why HALO maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$66.35
Potential Upside
847%
Whystock Fair Value$628.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$85.78+29.3%
Range$57.00 – $96.00
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.01
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
1141.64%
Volume
Today's trading volume
1.03M
Recent News
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 Guidance
Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]
How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFO
Halozyme Therapeutics recently announced that Darren Snellgrove, a veteran finance leader with more than 30 years of biopharma experience including senior roles at Johnson & Johnson, will become its Chief Financial Officer on June 8, 2026, overseeing financial operations, capital allocation, corporate development, and investor relations. Snellgrove’s background combining investor relations leadership and oversight of a Johnson & Johnson pharmaceuticals business generating over...
How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution Risk
Halozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...